Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20428009 | 0.87 | TAAR1 (0.50) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL20427978 | 0.83 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2TAAR1RIPK1 | |
| SCHEMBL4403486 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL20441553 | 0.78 | RIPK1 (0.49) | TAAR1RIPK1 | |
| SCHEMBL20988671 | 0.77 | RIPK1 (0.47) | ALDH1A1TAAR1RIPK1MEN1KMT2A | |
| SCHEMBL13077106 | 0.74 | BRS3 (0.41) | ALDH1A1MEN1KMT2AHTTPOLB | |
| SCHEMBL10438220 | 0.74 | CYP3A4 (0.37) | ALDH1A1SMN1; SMN2TAAR1TSHR | |
| SCHEMBL20428033 | 0.74 | TAAR1 (0.40) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL22728373 | 0.72 | KDM4E (0.34) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL91337 | 0.71 | KDM4E (0.45) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9804168-B2 | Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics | OPKO PHARMACEUTICALS, LLC (US) | 2017-10-31 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | KDM4E 1791/4885ALDH1A1 780/4885SMN1; SMN2 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.